Revolution Medicines, Inc. RVMD NASDAQ

Revolution Medicines, Inc. (RVMD) reported total assets of $2.35B and total liabilities of $723.21M for fiscal year 2025, resulting in total equity of $1.63B.

The company held $2.03B in cash and short-term investments. Total debt stood at $158.7M, with net debt of $-225.04M. The Debt-to-Equity (D/E) ratio was 0.1 (conservative).

Current ratio is 7.14, indicating strong short-term liquidity. Interest coverage is -48.8x (weak).

Criteria supported by this page:

• HEALTH (67/100, Partial) — some metrics are adequate but not all reach ideal thresholds
• MOAT (68/100) — Total assets $2.35B and equity $1.63B support the company's competitive scale
• VALUE (53/100) — Debt-to-Equity 0.1 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 43/100 with 1/7 criteria passed.

BPMC

Blueprint Medicines Corporation

$129.46

+0.14%

KYMR

Kymera Therapeutics, Inc.

$89.87

+1.51%

PTGX

Protagonist Therapeutics, Inc.

$104.72

+7.33%

AKRO

Akero Therapeutics, Inc.

$54.65

+0.00%

STOK

Stoke Therapeutics, Inc.

$35.86

+2.31%

AGIO

Agios Pharmaceuticals, Inc.

$33.30

+0.45%

NRIX

Nurix Therapeutics, Inc.

$16.30

+2.45%

GLUE

Monte Rosa Therapeutics, Inc.

$17.50

-0.28%